Please login to the form below

Not currently logged in
Email:
Password:

ruxolitinib

This page shows the latest ruxolitinib news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts haematology pipeline with $7bn Impact Bio deal

Celgene boosts haematology pipeline with $7bn Impact Bio deal

to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib), which grew 35% to $831m in the first nine months of 2017.

Latest news

More from news
Approximately 9 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics